Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA, Peacock NW, Shastry M, Burris HA 3rd, Bechhold RG, Hendricks CB, Yoshizawa CN, Sing AP, Hainsworth JD. Yardley DA, et al. Among authors: peacock nw. Breast Cancer Res Treat. 2015 Nov;154(2):299-308. doi: 10.1007/s10549-015-3613-y. Epub 2015 Oct 27. Breast Cancer Res Treat. 2015. PMID: 26507191 Clinical Trial.
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA, Peacock N, Daniel B, Anz B, Molthrop DC Jr, Shroff SK, Young R, Jankov A, Vander Woude A, Shastry M, Pasek J, DeBusk LM, Hainsworth JD. Yardley DA, et al. Breast Cancer Res Treat. 2020 Apr;180(3):647-655. doi: 10.1007/s10549-020-05563-z. Epub 2020 Feb 14. Breast Cancer Res Treat. 2020. PMID: 32060783 Clinical Trial.
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. Yardley DA, et al. Clin Breast Cancer. 2022 Apr;22(3):269-278. doi: 10.1016/j.clbc.2021.10.011. Epub 2021 Oct 28. Clin Breast Cancer. 2022. PMID: 34824002 Clinical Trial.
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
Yardley DA, Burris HA 3rd, Farley CP, Barton JH, Peacock NW, Spigel DR, Greco FA, Hainsworth JD. Yardley DA, et al. Among authors: peacock nw. Clin Breast Cancer. 2008 Jun;8(3):242-8. doi: 10.3816/CBC.2008.n.027. Clin Breast Cancer. 2008. PMID: 18650154 Clinical Trial.
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Yardley DA, Bosserman LD, O'Shaughnessy JA, Harwin WN, Morgan SK, Priego VM, Peacock NW, Bass JD, Burris HA 3rd, Hainsworth JD. Yardley DA, et al. Among authors: peacock nw. Breast Cancer Res Treat. 2015 Nov;154(1):89-97. doi: 10.1007/s10549-015-3599-5. Epub 2015 Oct 12. Breast Cancer Res Treat. 2015. PMID: 26456573 Clinical Trial.
21 results